Faecal haemoglobin concentration influences risk prediction of interval cancers resulting from inadequate colonoscopy quality: Analysis of the Taiwanese Nationwide Colorectal Cancer Screening Program

Gut

Volumn 66, Issue 2, 2017, Pages 293-300

  Chiu, Sherry Yueh Hsia ^a   Chuang, Shu Ling ^b   Chen, Sam Li Sheng ^c   Yen, Amy Ming Fang ^c   Fann, Jean Ching Yuan ^d   Chang, Dun Cheng ^e   Lee, Yi Chia ^f   Wu, Ming Shiang ^f   Chou, Chu Kuang ^g   Hsu, Wen Feng ^f   Chiou, Shu Ti ^e,h   Chiu, Han Mo ^f  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d KAINAN UNIVERSITY   (Taiwan)

^e Ministry of Health and Welfare   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^g CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^h NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN F; HEMOGLOBIN;

ADULT; AGE; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; FECAL IMMUNOCHEMICAL TESTING; FEMALE; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREDICTION; ADENOMA; CHEMISTRY; COLORECTAL NEOPLASMS; EARLY CANCER DIAGNOSIS; EPIDEMIOLOGY; FECES; MIDDLE AGED; OCCULT BLOOD; PREDICTIVE VALUE; PROGRAM EVALUATION; RISK ASSESSMENT; STANDARDS; TAIWAN;

ADENOMA; AGED; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FECES; FEMALE; HEMOGLOBINS; HUMANS; IMMUNOCHEMISTRY; MALE; MIDDLE AGED; OCCULT BLOOD; PREDICTIVE VALUE OF TESTS; PROGRAM EVALUATION; RISK ASSESSMENT; TAIWAN;

EID: 84946887613     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-310256     Document Type: Article

References (42)

1. Sung JJ, Lau JY, Goh KL, et al. Asia Pacific Working Group on Colorectal C. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 2005;6:871-6.
2. Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012;366:687-96.
3. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977-81.
4. Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008;103:1541-9.
5. Benson VS, Atkin WS, Green J, et al. Toward standardizing and reporting colorectal cancer screening indicators on an international level: The International Colorectal Cancer Screening Network. Int J Cancer 2012;130:2961-73.
6. Chiu HM, Chen SL, Yen AM, et al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. Cancer 2015;121:3221-9.
7. Singh H, Nugent Z, Mahmud SM, et al. Predictors of colorectal cancer after negative colonoscopy: a population-based study. Am J Gastroenterol 2010;105:663-73.
8. Baxter NN, Sutradhar R, Forbes SS, et al. Analysis of administrative data finds endoscopist quality measures associated with postcolonoscopy colorectal cancer. Gastroenterology 2011;140:65-72.
9. Robertson DJ, Lieberman DA, Winawer SJ, et al. Colorectal cancers soon after colonoscopy: a pooled multicohort analysis. Gut 2014;63:949-56.
10. Rabeneck L, Paszat LF, Saskin R. Endoscopist specialty is associated with incident colorectal cancer after a negative colonoscopy. Clin Gastroenterol Hepatol 2010;8:275-9.
11. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010;362:1795-803.
12. Brenner H, Chang-Claude J, Seiler CM, et al. Interval cancers after negative colonoscopy: population-based case-control study. Gut 2012;61:1576-82.
13. Corley DA, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014;370:1298-306.
14. Hassan C, Rex DK, Zullo A, et al. Loss of efficacy and cost-effectiveness when screening colonoscopy is performed by nongastroenterologists. Cancer 2012;118:4404-11.
15. Auge JM, Pellise M, Escudero JM, et al. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program. Gastroenterology 2014;147:628-36 e1.
16. Liao CS, Lin YM, Chang HC, et al. Application of quantitative estimates of fecal hemoglobin concentration for risk prediction of colorectal neoplasia. World J Gastroenterol 2013;19:8366-72.
17. Hol L, Wilschut JA, van Ballegooijen M, et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009;100:1103-10.
18. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007;146:244-55.
19. Chen LS, Yen AM, Chiu SY, et al. Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort. Lancet Oncol 2011;12:551-8.
20. Chiang TH, Chuang SL, Chen SL, et al. Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program. Gastroenterology 2014;147:1317-26.
21. Hamilton SR, Aaltonen LA. Pathology and genetics of tumours of the digestive system. World Health Organization classification of tumours. Lyon: IARC Press, 2000.
22. Sanduleanu S, le Clercq CM, Dekker E, et al. Definition and taxonomy of interval colorectal cancers: a proposal for standardising nomenclature. Gut 2015;64:1257-67.
23. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012;143:844-57.
24. le Clercq CM, Bouwens MW, Rondagh EJ, et al. Postcolonoscopy colorectal cancers are preventable: a population-based study. Gut 2014;63:957-63.
25. Grazzini G, Ventura L, Zappa M, et al. Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district. Gut 2010;59:1511-15.
26. Sanduleanu S, Masclee AM, Meijer GA. Interval cancers after colonoscopy-insights and recommendations. Nat Rev Gastroenterol Hepatol 2012;9:550-4.
27. Singh H, Nugent Z, Demers AA, et al. Rate and predictors of early/missed colorectal cancers after colonoscopy in Manitoba: a population-based study. Am J Gastroenterol 2010;105:2588-96.
28. Baxter NN, Warren JL, Barrett MJ, et al. Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. J Clin Oncol 2012;30:2664-9.
29. Baxter NN, Goldwasser MA, Paszat LF, et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009;150:1-8.
30. Brenner H, Chang-Claude J, Jansen L, et al. Role of colonoscopy and polyp characteristics in colorectal cancer after colonoscopic polyp detection: a population-based case-control study. Ann Intern Med 2012;157: 225-32.
31. Rembacken B, Hassan C, Riemann JF, et al. Quality in screening colonoscopy: position statement of the European Society of Gastrointestinal Endoscopy (ESGE). Endoscopy 2012;44:957-68.
32. Rex DK, Petrini JL, Baron TH, et al. Quality indicators for colonoscopy. Am J Gastroenterol 2006;101:873-85.
33. Chilton A. NHS BCSP Quality Assurance Guidelines for Colonoscopy. NHS Cancer Screening Programmes website for England, 2011. http://www.cancerscreening. nhs.uk/bowel/publications/nhsbcsp06.pdf (Accessed on Oct 23, 2015).
34. Martínez ME, Baron JA, Lieberman DA, et al. A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology 2009;136:832-41.
35. Chung SJ, Kim YS, Yang SY, et al. Five-year risk for advanced colorectal neoplasia after initial colonoscopy according to the baseline risk stratification: a prospective study in 2452 asymptomatic Koreans. Gut 2011;60:1537-43.
36. Chiu HM, Lee YC, Tu CH, et al. Effects of metabolic syndrome and findings from baseline colonoscopies on occurrence of colorectal neoplasms. Clin Gastroenterol Hepatol 2015;13:1134-42.
37. Soetikno RM, Kaltenbach T, Rouse RV, et al. Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. JAMA 2008;299:1027-35.
38. Chiu HM, Lin JT, Chen CC, et al. Prevalence and characteristics of nonpolypoid colorectal neoplasm in an asymptomatic and average-risk Chinese population. Clin Gastroenterol Hepatol 2009;7:463-70.
39. Matsuda T, Saito Y, Hotta K, et al. Prevalence and clinicopathological features of nonpolypoid colorectal neoplasms: should we pay more attention to identifying flat and depressed lesions Dig Endosc 2010;22(Suppl 1):S57-62.
40. Shaukat A, Arain M, Thaygarajan B, et al. Is BRAF mutation associated with interval colorectal cancers Dig Dis Sci 2010;55:2352-6.
41. Lane JM, Chow E, Young GP, et al. Interval fecal immunochemical testing in a colonoscopic surveillance program speeds detection of colorectal neoplasia. Gastroenterology 2010;139:1918-26.
42. Fraser CG, Allison JE, Halloran SP, et al. Expert Working Group on Fecal Immunochemical Tests for Hemoglobin CCSCWEO. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst 2012;104:810-14.